Document is current
Any future updates will be listed below
-
Authors
Cagnone, Gael
Pundir, Sheetal
Betus, Charlotte
Agnihotri, Tapan
Ren, Anli
-Kim, Jin Sung https://orcid.org/0000-0002-7823-3563
Harvey, Noémie-Rose
Heckel, Emilie
Chen, Mei Xi
Situ, Anu
Gaub, Perrine
Kim, Nicholas
Das, Ashim
Leclerc, Severine https://orcid.org/0000-0002-1485-4897
Wünnemann, Florian
Berillon, Louis
Andelfinger, Gregor
Crespo-Garcia, Sergio
Dubrac, Alexandre https://orcid.org/0000-0002-3829-2577
Rezende, Flavio A.
Clish, Clary B. https://orcid.org/0000-0001-8259-9245
Maranda, Bruno
Rivera, José Carlos
Smith, Lois E. H.
Sapieha, Przemyslaw https://orcid.org/0000-0002-9171-2825
Joyal, Jean-Sébastien
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (353770)
Heart and Stroke Foundation of Canada (G-16-00014658)
Canadian Diabetes Association (DI-3-18-5444-PS)
- License Information
-
More Information
Article History
Received: 6 December 2023
Accepted: 13 May 2025
First Online: 25 June 2025
Competing interests
: The authors have no conflicts of interest to declare relevant to this article’s content. F.R. is an advisory board member for Bayer AG (Germany) and F. Hoffmann-La Roche AG (Switzerland). P.S. is the founder and Chief Scientific Officer of SemaThera Inc. (Montreal, Canada) and Chief Scientist of UNITY Biotechnology (California, US) and holds equity in both companies.
